Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Gastroenterology
Published in: Journal of Gastroenterology 11/2014

01-11-2014 | Editorial

How much management is necessary? Sustaining the benefit of achieving a sustained virologic response to hepatitis C

Author: Rebecca L. Morgan

Published in: Journal of Gastroenterology | Issue 11/2014

Login to get access

Excerpt

Described as a silent killer by the media, hepatitis C virus (HCV) infection can be present in the body for 20 years or more before causing serious complications. An estimated 130–150 million persons globally are infected with HCV, among which 350,000–500,000 deaths each year can be attributed to HCV, including HCV-related liver disease, cirrhosis, and hepatocellular carcinoma (HCC) [1]. With appropriate screening and treatment, many of these deaths can be prevented. …
Literature
1.
World Health Organization (WHO). Guidelines for the screening, care and treatment of persons with hepatitis C infection. 2014.
2.
Gaetano JN. Benefit–risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir. Drug Healthc Patient Saf. 2014;6:37–45.PubMedCentralPubMedCrossRef
3.
Muir AJ. The rapid evolution of treatment strategies for hepatitis C. Am J Gastroenterol. 2014;109(5):628–35.PubMedCrossRef
4.
5.
European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60(2):392–420.CrossRef
6.
Yamashita N, Ohho A, Yamasaki A, Kurokawa M, Kotoh K, Kajiwara E. Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes. J Gastroenterol. 2013;. doi:10.​1007/​s00535-013-0921-z.
7.
Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158(5 Pt 1):329–37.PubMedCrossRef
Metadata
Title
How much management is necessary? Sustaining the benefit of achieving a sustained virologic response to hepatitis C
Author
Rebecca L. Morgan
Publication date
01-11-2014
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 11/2014
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-014-0990-7

Other articles of this Issue 11/2014

Journal of Gastroenterology 11/2014 Go to the issue

Original Article—Alimentary Tract

A gene expression profile related to immune dampening in the tumor microenvironment is associated with poor prognosis in gastric adenocarcinoma

Original Article—Liver, Pancreas, and Biliary Tract

Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study

Original Article—Alimentary Tract

Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome

Original Article—Alimentary Tract

The opposite prognostic significance of nuclear and cytoplasmic p21 expression in resectable gastric cancer patients

Original Article—Liver, Pancreas, and Biliary Tract

Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients

Original Article—Liver, Pancreas, and Biliary Tract

Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits